News - TOSP

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors

03 May 2023

— Renowned thought leader in computational biology and data science for cancer research — — Over 180 publications on the evolutionary dynamics of cancer initiation, progression, response to therapy and emergence of resistance — OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors. Prof. Michor is a professor of Computational Biology... Read more

TOSP is delighted to be supporting BioTrinity again! See us on stand 10.

14 Apr 2023

BioTrinity is a great conference to hear about the latest developments in life sciences and make new contacts. We'll be at stand 10, talking about our pipeline of new state-of-the art lab and office buildings, perfect grow-on space for innovative companies. Details here. Read more

Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics

14 Apr 2023

Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics Fri 14th April 2023 Oxford Nanopore Technologies and bioMérieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics... Read more

Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals

03 Apr 2023

New Jersey, USA, and Oxford, UK: Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers... Read more

Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

03 Apr 2023

OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round. Plutus Investment Group LLP led the round, with participation from new and existing investors including UK-based VC funds Esperante Ventures, Longwall Ventures and Panacea Innovation, alongside entrepreneur and professional investor, Mr BK Lee. Funds will be used to... Read more